Seagen gets Au­gust PDU­FA for Pad­cev ex­pan­sions

Seagen gets Au­gust PDU­FA for Pad­cev ex­pan­sions

Source: 
Endpoints
snippet: 

Seagen is riding the wave of two new priority reviews straight to the FDA.

The Bothell, WA-based biotech and their partners at Astellas announced Monday that two supplemental BLAs for Padcev had been accepted by US regulators. FDA has set Aug. 17 as the PDUFA date for the reviews.